24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
BioGenCell
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
08:38
CTech’s Book Review: The guide to stellar sales
17:49
EU antitrust chief Vestager ends with wins over Apple and Google, but is it enough?
16:25
Larry Ellison-backed Israeli startup Imagene and Oracle unveil AI model for cancer detection
15:30
Eyal Waldman joins Cato Networks' Board as cyber unicorn prepares for 2025 IPO
More stories
Buzz
Most popular
Daily
Weekly
1
Cyber unicorn Checkmarx hits the market with $2.5 billion price tag
2
"We closed a deal with a large client, but they had questions about what happens if Israel no longer exists"
3
Andreessen Horowitz steps up Israeli investments as local funds struggle to raise capital
4
Mobileye drops lidar development, axes 100 jobs to save $60M
5
The Gili Ra’anan model: Questions emerging from Cyberstarts' remarkable success
More news
BioGenCell
1 stories about BioGenCell
BioGenCell pioneers revolutionary cell therapy for microvascular disease
11.07.24
|
Ariela Karmel
CEO Yael Porat spoke to CTech about the Israeli biotech company’s groundbreaking cell therapy technology for the common and debilitating disease whose primary treatment today is amputation
Please ensure Javascript is enabled for purposes of
website accessibility